# Slingshot Biosciences

> Slingshot Biosciences makes manufactured cell mimics that give flow cytometry labs stable reference materials for instrument checks, fluorescence compensation, biomarker assays and cell therapy quality control. Founded in 2012 in Emeryville, it moved from an instrument-maker's narrow calibration problem to a catalog of off-the-shelf and custom controls used by research, diagnostics and biopharma teams worldwide.

- **Founded:** 2012
- **Headquarters:** Emeryville, United States
- **Founders:** Jeffrey Kim (Co-founder and former CEO)
- **Products:** FlowCytes, SpectraComp, ViaComp, TruCytes, StimCytes
- **Notable:** Raised $34 million across the disclosed 2021 Series A and 2023 Series A3 rounds., Expanded from instrument controls into a cell therapy-focused portfolio in 2024-2025., Reported hundreds of customer organizations worldwide in February 2026.

## Products & services

- **FlowCytes** — Synthetic white-blood-cell-like scatter controls for standardizing flow cytometer settings and checking instruments.
- **SpectraComp** — Single-stain cell mimics for spectral unmixing and fluorescence compensation.
- **ViaComp** — Viability and compensation controls, including the Ultra XT Amine single-vial format launched in 2026.
- **TruCytes** — Off-the-shelf and custom biomarker controls for immunophenotyping, assay validation and cell therapy applications.
- **StimCytes** — Functional CAR-T potency benchmarking cell mimics, including BCMA and CD19 related controls.
- **ScatterBridge, PhenoCytes and QuantCytes** — Additional controls for instrument harmonization, phenotype matching and quantitative antigen-density work.

## Achievements

- Raised $34 million across the disclosed 2021 Series A and 2023 Series A3 rounds.
- Expanded from instrument controls into a cell therapy-focused portfolio in 2024-2025.
- Reported hundreds of customer organizations worldwide in February 2026.
- Announced UK and EU market expansion in February 2026.
- Integrated TruCytes into Cellares' Cell Q automated QC platform in 2025.

## Latest updates

- **2026-09** — Nimisha Srivastava became CEO, effective September 23, succeeding Glenn Bilawsky.
- **2026-08** — Launched ViaComp Ultra XT Amine, a single-vial control for viability dye and antibody unmixing or compensation.
- **2026-03** — Appointed Jim Snook senior vice president of global sales.
- **2026-02** — Announced an expansion in the UK and EU markets.
- **2025-10** — Announced a Cellares collaboration and new TruCytes CD20 potency and CD34 stem-cell gating controls.

## Links

- Website: https://www.slingshotbio.com/
- LinkedIn: https://www.linkedin.com/company/slingshot-biosciences/
- Twitter/X: https://twitter.com/slingshotbio
- Facebook: https://facebook.com/p/Slingshot-Biosciences-100083011733219/

---

Profile page: https://yespress.io/slingshot-biosciences
Published by YesPress — https://yespress.io
Last updated: 2026-09-29